EFFECTIVENESS OF USING THE PROBIOTIC "LACTIALE MULTI" IN THE COMPLEX TREATMENT OF PATIENTS FOR CORONAVIRUS DISEASE-2019
DOI:
https://doi.org/10.11603/1681-2727.2023.4.14248Keywords:
coronavirus disease-2019, psycho-neurological disorders, intestinal microflora, psychobioticsAbstract
SUMMARY. The purpose of the work is to investigate the effectiveness and safety profile of the probiotic "Lactiale Multi" in the complex therapy of patients with COVID-19 by studying its effect on psycho-neurological disorders and the state of the colon microflora.
Materials and methods. 85 patients with COVID-19 were examined, who were divided into two groups depending on the severity of the disease. Group I included 49 (57.65 %) patients with a moderate course, group II – 36 (42.35 %) patients with a severe course of COVID-19. At the next stage of the study, a patient questionnaire was conducted to assess the state of the central nervous system, and based on it, 66 (75.65 %) patients with psycho-neurological disorders were selected. Depending on the prescribed treatment, they were also divided into two groups, matched by age, sex, clinical stage of the disease, presence of concomitant diseases. The main group consisted of 33 (50.0 %) patients who, in addition to standard etiotropic and pathogenetic therapy, received the probiotic "Lactiale Multi" 1 capsule 2 times a day for 14 days. The comparison group included 33 (50 %) patients who received standard etiotropic and pathogenetic therapy.
Research results. Clinical manifestations of damage to the nervous system and/or mental disorders were observed in 34 (69.39 %) patients of group I (headache in 34 (69.39 %), sleep disturbances in 33 (67.35 %), lack of taste and smell in 21 (42.86 %), ataxia, anxiety in 15 (30.61 %), anxiety in 9 (18.37 %), suicidal thoughts in 7 (14.29 %), depression in 6 (12.24 %) , neuralgia in 5 (10.2 %) persons) and in 32 (88.89 %) patients of group II (headache in 32 (88.89 %), sleep disturbance in 29 (80.56 %), anxiety in 27 (75.0 %), lack of taste and smell in 27 (75.0 %), anxiety in 25 (69.44 %), depression in 14 (38.89 %), impaired consciousness in 7 (19.44 %), suicidal thoughts in 6 (16.67 %), ataxia in 5 (13.89 %), neuralgia in 5 (13.89 %) persons).
In the group of patients who received the probiotic "Lactiale Multi", the regression of psycho-neurological manifestations (headache, sleep disturbance, ataxia, suicidal thoughts, worry, anxiety, impaired taste and smell, depression) and restoration of the state of the intestinal microflora was observed earlier than in comparison group (р˂0.05).
Conclusions. The occurrence of psycho-neurological disorders is typical for the 2019 coronavirus disease. They are observed in the majority of patients (77.65 %) with a moderate and severe course of the disease against the background of deep dysbiotic changes in the form of a deficiency of bifido- and lactobacteria, a decrease in the content of lactose-positive and an increase in the content of lactose-negative escherichia, increased growth of fungal flora, the presence of hemolytic escherichia and staphylococcus aureus .
The use of the probiotic multistrain drug "Lactiale Multi" in the complex therapy of patients with COVID-19 contributes to the regression of clinical manifestations of damage to the nervous system and the restoration of the state of the intestinal microflora compared to standard therapy.
References
Kumar, A., Arora, A., Sharma, P., Anikhindi, S. A., Bansal, N., Singla, V., Khare, S., & Srivastava, A. (2020). Gastrointestinal and hepatic manifestations of Corona Virus Disease-19 and their relationship to severe clinical course: A systematic review and meta-analysis. Indian Journal Gastroenterology, 39(3), 268-284. DOI: 10.1007/s12664-020-01058-3. DOI: https://doi.org/10.1007/s12664-020-01058-3
Mao, R., Qiu, Y., He, J. S., Tan, J. Y., Li, X. H., Liang, J., … & Chen, M. H. (2020). Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology, 5(7), 667-678. DOI: 10.1016/S2468-1253(20)30126-6. DOI: https://doi.org/10.1016/S2468-1253(20)30126-6
Elshazli, R. M., Kline, A., Elgaml A., Aboutaleb, M. H., Salim, M. M., Omar, M., … & Kandil, E. (2021). Gastroenterology manifestations and COVID-19 outcomes: A meta-analysis of 25,252 cohorts among the first and second waves. J. Med. Virol., 93(5), 2740-2768. DOI: 10.1002/jmv.26836. DOI: https://doi.org/10.1002/jmv.26836
Salabei, J. K., Fishman, T. J., Asnake, Z. T., Ali, A., & Iyer, U. G. (2021). COVID-19 Coagulopathy: Current knowledge and guidelines on anticoagulation. Heart Lung, 50(2), 357-360. DOI: 10.1016/j.hrtlng.2021.01.011. DOI: https://doi.org/10.1016/j.hrtlng.2021.01.011
Choi, B., Choudhary, M. C., Regan, J., Sparks, J. A., Padera, R. F., Qiu, X., … & Li, J. Z. (2020). Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. New England Journal of Medicine, 383(23), 2291-2293. DOI: 10.1056/NEJMc2031364. DOI: https://doi.org/10.1056/NEJMc2031364
Hu, F., Chen, F., Ou, Z., Fan, Q., Tan, X., Wang, Y., … & Li, F. (2020). A compromised specific humoral immune response against the SARS-CoV-2 receptor-binding domain is related to viral persistence and periodic shedding in the gastrointestinal tract. Cell. & Mol. Immunol., 17, 1119-1125. DOI: 10.1038/s41423-020-00550-2. DOI: https://doi.org/10.1038/s41423-020-00550-2
Губергриц, Н. Б., Беляева, Н. В. & Можина, Т. Л. (2021). Фуга назначению пробиотиков при СОVID‑19: использовать или пренебречь? Здоровье Украины 21 век, (13-14), 18-21.
Megur A, Baltriukiene D, Bukelskiene V, Burokas A. The microbiota–gut–brain axis and alzheimer’s disease: neuroinflammation is to blame? Nutrients. (2020) 13:37. doi: 10.3390/nu13010037. DOI: https://doi.org/10.3390/nu13010037
Liu Y, Wang H, Gui S, Zeng B, Pu J, Zheng P, et al. Proteomics analysis of the gut–brain axis in a gut microbiota-dysbiosis model of depression. Transl Psychiatry. (2021) 11:1–8. doi: 10.1038/s41398-021-01689-w DOI: https://doi.org/10.1038/s41398-021-01689-w
Mörkl S, Butler MI, Holl A, Cryan JF, Dinan TG. Probiotics and the microbiota-gut-brain axis: focus on psychiatry. Curr Nutr Rep. (2020) 9:171–82. doi: 10.1007/s13668-020-00313-5. DOI: https://doi.org/10.1007/s13668-020-00313-5
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 К. В. Юрко, Г. О. Соломенник, В. В. Кучерявченко
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal Infectious Disease (Infektsiini Khvoroby) allows the author(s) to hold the copyright without registration
Users can use, reuse and build upon the material published in the journal but only for non-commercial purposes
This journal is available through Creative Commons (CC) License BY-NC "Attribution-NonCommercial" 4.0
